<p>在 Google 搜索和 AI 回答中查看更多来自 StockTitan 的信息。将 StockTitan 添加为首选来源 · 打开 Google</p>
<p>在 Google 上添加</p>
<p>Oculis Holding AG（纳斯达克：OCS；XICE：OCS）（“Oculis” 或 “公司”）是一家全球生物制药公司，专注于解决神经眼科和眼科疾病的创新，满足重大未满足的医疗需求，今天宣布 Oculis 管理层将参加第 47 届高盛全球医疗保健会议的炉边聊天。</p>
<p>公司将提供其创新的当前晚期产品组合的概述和更新。主要亮点包括：<strong>Privosegtor</strong>，一种新型神经保护候选药物，已获得美国食品药品监督管理局（FDA）的突破性疗法认证和欧洲药品管理局（EMA）的优先药物（PRIME）认证，用于视神经炎（ON），在 <strong>PIONEER</strong> 注册项目中，旨在满足两种视神经病的未满足需求，并在美国独自解锁超过 70 亿美元的潜在市场机会，以及 <strong>Licaminlimab</strong>，一种局部抗 TNFα药物，正在 <strong>PREDICT-1</strong> 注册试验中评估，作为干眼病（DED）中首个基于基因型的精准医学。</p>
<p>凭借强大的资产负债表和先进的产品管线，Oculis 准备在当前资金的支持下交付多个关键结果，专注于实现其拯救视力和改善眼科护理的使命，提供突破性治疗。</p>
<p><strong>第 47 届高盛全球医疗保健会议</strong></p>
<p>日期：6 月 9 日，东部时间下午 4:00</p>
<p>地点：佛罗里达州迈阿密</p>
<p>形式：炉边聊天</p>
<p>演讲者：Riad Sherif 博士，首席执行官</p>
<p>网络直播链接：在此注册</p>
<p>公司将在会议期间提供一对一会议。感兴趣的投资者应联系其各自的代表，向赞助机构请求会议。</p>
<p>网络直播链接在可用时会发布在 Oculis 网站的投资者与媒体部分的活动与演示页面上。</p>
<p><strong>-结束-</strong></p>
<p><strong>关于 Oculis</strong></p>
<p>Oculis 是一家全球生物制药公司（纳斯达克：OCS；XICE：OCS），专注于突破性创新，以解决神经眼科和眼科领域中重大未满足的医疗需求。Oculis 的高度差异化的晚期临床管线专注于两个核心产品候选药物。Privosegtor 是 PIONEER 项目中的突破性神经保护候选药物，该项目包括旨在支持视神经病（包括视神经炎（ON）和非动脉性前缺血性视神经病（NAION）治疗注册计划的研究。Privosegtor 还具有在其他神经眼科和神经疾病中开发额外适应症的潜力。Licaminlimab 是一种新型局部抗 TNFα药物，正在进行注册试验，并采用基因型基础的方法开发，用于治疗干眼病（DED）患者。Oculis 总部位于瑞士，在美国、冰岛和瑞士开展业务，由经验丰富的管理团队领导，拥有成功的业绩记录，并得到领先国际医疗投资者的支持。</p>
<p>欲了解更多信息，请访问：www.oculis.com</p>
<p><strong>Oculis 联系方式</strong></p>
<p>Sylvia Cheung，首席财务官</p>
<p>sylvia.cheung@oculis.com</p>
<p><strong>投资者关系</strong></p>
<p>LifeSci Advisors</p>
<p>Corey Davis，博士</p>
<p>cdavis@lifesciadvisors.com</p>
<p><strong>媒体关系</strong></p>
<p>ICR Healthcare</p>
<p>Amber Fennell / David Daley / Sean Leous</p>
<p>oculis@icrhealthcare.com</p>
<p><strong>关于前瞻性声明的警示声明</strong></p>
<p>本新闻稿包含前瞻性声明和信息。例如，关于公司产品候选药物潜在益处的声明，包括当前和未来临床试验的启动、时间、进展和结果，Oculis 的研究和开发计划，监管和商业战略；预期里程碑；关于市场机会的声明；以及关于现金流和资本需求的声明，均为前瞻性声明。所有前瞻性声明均基于估计和假设，尽管 Oculis 及其管理层认为这些假设合理，但本质上是不确定的，并且本质上受到许多超出 Oculis 控制的风险、变数和意外情况的影响。这些前瞻性声明仅供说明目的，并不打算作为投资者的保证、保证、预测或事实或概率的明确声明。实际事件和情况难以或不可能预测，并将与假设不同。所有前瞻性声明均受到风险、不确定性和其他因素的影响，这些因素可能导致实际结果与我们预期的结果和/或这些前瞻性声明所表达或暗示的结果有实质性差异。前瞻性声明受到许多条件的限制，其中许多超出了 Oculis 的控制，包括在 Oculis 的 20-F 表格年报和任何其他提交给 SEC 的文件中列出的风险因素部分。这些文件的副本可在 SEC 网站 www.sec.gov 上获得。Oculis 没有义务在本发布日期后更新这些声明以进行修订或更改，除非法律要求。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9TVRBd01URTROalU0TXlNME1ESTBNRFUzTWpZak1qRTRPVEF5TXc9PQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9TVRBd01URTROalU0TXlNME1ESTBNRFUzTWpZak1qRTRPVEF5TXc9PQ"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml-eu.globenewswire.com/media/ZDgzMzk3ZTUtMGYyYy00ZGZkLTgxZWQtYWI5M2VkNTg2YWU4LTEyMDA1NzYtMjAyNi0wNi0wOC1lbg==/tiny/Oculis-Holding-AG.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml-eu.globenewswire.com/media/ZDgzMzk3ZTUtMGYyYy00ZGZkLTgxZWQtYWI5M2VkNTg2YWU4LTEyMDA1NzYtMjAyNi0wNi0wOC1lbg==/tiny/Oculis-Holding-AG.png"/></p>

<p>Oculis Holding AG（纳斯达克代码：OCS）宣布，其管理层将在首席执行官 Dr. Riad Sherif 的带领下，参加于 6 月 9 日在迈阿密举行的第 47 届高盛全球医疗健康会议的炉边谈话。公司将概述其晚期产品组合，重点介绍用于视神经炎的 Privosegtor 和用于干眼症的 Licaminlimab</p>

<p>See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google</p>
<div class="lb-trans"><p>在 Google 搜索和 AI 回答中查看更多来自 StockTitan 的信息。将 StockTitan 添加为首选来源 · 打开 Google</p>
</div><p>Add on Google</p>
<div class="lb-trans"><p>在 Google 上添加</p>
</div><p>Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs, announced today that Oculis’ management will participate in a fireside chat at the 47th Annual Goldman Sachs Global Healthcare Conference.</p>
<div class="lb-trans"><p>Oculis Holding AG（纳斯达克：OCS；XICE：OCS）（“Oculis” 或 “公司”）是一家全球生物制药公司，专注于解决神经眼科和眼科疾病的创新，满足重大未满足的医疗需求，今天宣布 Oculis 管理层将参加第 47 届高盛全球医疗保健会议的炉边聊天。</p>
</div><p>The Company will provide an overview and update of its innovative current late-stage portfolio. Key highlights include: <strong>Privosegtor</strong>, a novel neuroprotective candidate which received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for optic neuritis (ON), in the <strong>PIONEER</strong> registrational program to address unmet needs for two optic neuropathies and to unlock a potential market opportunity of $7B+ in the U.S. alone, and <strong>Licaminlimab</strong>, a topical anti-TNFα being evaluated in the <strong>PREDICT-1</strong> registrational trial as the first genotype-based precision medicine in dry eye disease (DED).</p>
<div class="lb-trans"><p>公司将提供其创新的当前晚期产品组合的概述和更新。主要亮点包括：<strong>Privosegtor</strong>，一种新型神经保护候选药物，已获得美国食品药品监督管理局（FDA）的突破性疗法认证和欧洲药品管理局（EMA）的优先药物（PRIME）认证，用于视神经炎（ON），在 <strong>PIONEER</strong> 注册项目中，旨在满足两种视神经病的未满足需求，并在美国独自解锁超过 70 亿美元的潜在市场机会，以及 <strong>Licaminlimab</strong>，一种局部抗 TNFα药物，正在 <strong>PREDICT-1</strong> 注册试验中评估，作为干眼病（DED）中首个基于基因型的精准医学。</p>
</div><p>With a strong balance sheet and advanced pipeline, Oculis prepares to deliver several pivotal readouts with the current funding, focusing on fulfilling its mission to save sight and improve eye care with groundbreaking treatments.</p>
<div class="lb-trans"><p>凭借强大的资产负债表和先进的产品管线，Oculis 准备在当前资金的支持下交付多个关键结果，专注于实现其拯救视力和改善眼科护理的使命，提供突破性治疗。</p>
</div><p><strong>47th Annual Goldman Sachs Global Healthcare Conference</strong></p>
<div class="lb-trans"><p><strong>第 47 届高盛全球医疗保健会议</strong></p>
</div><p>Date: June 9, 4:00pm ET</p>
<div class="lb-trans"><p>日期：6 月 9 日，东部时间下午 4:00</p>
</div><p>Location: Miami, FL</p>
<div class="lb-trans"><p>地点：佛罗里达州迈阿密</p>
</div><p>Format: Fireside chat</p>
<div class="lb-trans"><p>形式：炉边聊天</p>
</div><p>Presenter: Dr. Riad Sherif, CEO</p>
<div class="lb-trans"><p>演讲者：Riad Sherif 博士，首席执行官</p>
</div><p>Webcast link: Register here</p>
<div class="lb-trans"><p>网络直播链接：在此注册</p>
</div><p>The Company will be available for one-on-one meetings during the conference. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.</p>
<div class="lb-trans"><p>公司将在会议期间提供一对一会议。感兴趣的投资者应联系其各自的代表，向赞助机构请求会议。</p>
</div><p>Webcast links, when available, are posted to the Oculis website on the Events &amp; Presentations page under the Investors &amp; Media section.</p>
<div class="lb-trans"><p>网络直播链接在可用时会发布在 Oculis 网站的投资者与媒体部分的活动与演示页面上。</p>
</div><p><strong>-ENDS-</strong></p>
<div class="lb-trans"><p><strong>-结束-</strong></p>
</div><p><strong>About Oculis</strong></p>
<div class="lb-trans"><p><strong>关于 Oculis</strong></p>
</div><p>Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline focuses on two core product candidates. Privosegtor is a breakthrough neuroprotective candidate in the PIONEER program, which consists of studies intended to support registration plans for treatment of optic neuropathies, including optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION). Privosegtor also has potential to be developed for additional indications in other neuro-ophthalmic and neurological diseases. Licaminlimab is a novel, topical anti-TNFα in a registrational trial, and is being developed with a genotype-based approach for treating patients with dry eye disease (DED). Headquartered in Switzerland with operations in the U.S., Iceland and Switzerland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.</p>
<div class="lb-trans"><p>Oculis 是一家全球生物制药公司（纳斯达克：OCS；XICE：OCS），专注于突破性创新，以解决神经眼科和眼科领域中重大未满足的医疗需求。Oculis 的高度差异化的晚期临床管线专注于两个核心产品候选药物。Privosegtor 是 PIONEER 项目中的突破性神经保护候选药物，该项目包括旨在支持视神经病（包括视神经炎（ON）和非动脉性前缺血性视神经病（NAION）治疗注册计划的研究。Privosegtor 还具有在其他神经眼科和神经疾病中开发额外适应症的潜力。Licaminlimab 是一种新型局部抗 TNFα药物，正在进行注册试验，并采用基因型基础的方法开发，用于治疗干眼病（DED）患者。Oculis 总部位于瑞士，在美国、冰岛和瑞士开展业务，由经验丰富的管理团队领导，拥有成功的业绩记录，并得到领先国际医疗投资者的支持。</p>
</div><p>For more information, please visit: www.oculis.com</p>
<div class="lb-trans"><p>欲了解更多信息，请访问：www.oculis.com</p>
</div><p><strong>Oculis Contacts</strong></p>
<div class="lb-trans"><p><strong>Oculis 联系方式</strong></p>
</div><p>Sylvia Cheung, CFO</p>
<div class="lb-trans"><p>Sylvia Cheung，首席财务官</p>
</div><p>sylvia.cheung@oculis.com</p>
<div class="lb-trans"><p>sylvia.cheung@oculis.com</p>
</div><p><strong>Investor Relations</strong></p>
<div class="lb-trans"><p><strong>投资者关系</strong></p>
</div><p>LifeSci Advisors</p>
<div class="lb-trans"><p>LifeSci Advisors</p>
</div><p>Corey Davis, Ph.D.</p>
<div class="lb-trans"><p>Corey Davis，博士</p>
</div><p>cdavis@lifesciadvisors.com</p>
<div class="lb-trans"><p>cdavis@lifesciadvisors.com</p>
</div><p><strong>Media Relations</strong></p>
<div class="lb-trans"><p><strong>媒体关系</strong></p>
</div><p>ICR Healthcare</p>
<div class="lb-trans"><p>ICR Healthcare</p>
</div><p>Amber Fennell / David Daley / Sean Leous</p>
<div class="lb-trans"><p>Amber Fennell / David Daley / Sean Leous</p>
</div><p>oculis@icrhealthcare.com</p>
<div class="lb-trans"><p>oculis@icrhealthcare.com</p>
</div><p><strong>Cautionary Statement Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性声明的警示声明</strong></p>
</div><p>This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company’s product candidates, including the initiation, timing, progress and results of current and future clinical trials, Oculis’ research and development programs, regulatory and business strategy; expected milestones; statements about market opportunity; and statements about cash runway and capital needs, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the SEC. Copies of these documents are available on the SEC’s website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law</p>
<div class="lb-trans"><p>本新闻稿包含前瞻性声明和信息。例如，关于公司产品候选药物潜在益处的声明，包括当前和未来临床试验的启动、时间、进展和结果，Oculis 的研究和开发计划，监管和商业战略；预期里程碑；关于市场机会的声明；以及关于现金流和资本需求的声明，均为前瞻性声明。所有前瞻性声明均基于估计和假设，尽管 Oculis 及其管理层认为这些假设合理，但本质上是不确定的，并且本质上受到许多超出 Oculis 控制的风险、变数和意外情况的影响。这些前瞻性声明仅供说明目的，并不打算作为投资者的保证、保证、预测或事实或概率的明确声明。实际事件和情况难以或不可能预测，并将与假设不同。所有前瞻性声明均受到风险、不确定性和其他因素的影响，这些因素可能导致实际结果与我们预期的结果和/或这些前瞻性声明所表达或暗示的结果有实质性差异。前瞻性声明受到许多条件的限制，其中许多超出了 Oculis 的控制，包括在 Oculis 的 20-F 表格年报和任何其他提交给 SEC 的文件中列出的风险因素部分。这些文件的副本可在 SEC 网站 www.sec.gov 上获得。Oculis 没有义务在本发布日期后更新这些声明以进行修订或更改，除非法律要求。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9TVRBd01URTROalU0TXlNME1ESTBNRFUzTWpZak1qRTRPVEF5TXc9PQ" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTE4NjU4MyM0MDI0MDU3MjYjMjE4OTAyMw=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml-eu.globenewswire.com/media/ZDgzMzk3ZTUtMGYyYy00ZGZkLTgxZWQtYWI5M2VkNTg2YWU4LTEyMDA1NzYtMjAyNi0wNi0wOC1lbg==/tiny/Oculis-Holding-AG.png" alt="" original-src="https://ml-eu.globenewswire.com/media/ZDgzMzk3ZTUtMGYyYy00ZGZkLTgxZWQtYWI5M2VkNTg2YWU4LTEyMDA1NzYtMjAyNi0wNi0wOC1lbg==/tiny/Oculis-Holding-AG.png"/></p>

Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference | OCS Stock News

StockTitan

Oculis 将在第 47 届年度高盛全球医疗保健会议上发表演讲 | OCS 股票新闻